BIOFRONTERA AG/ADR (NASDAQ:BFRA) Stock Price Up 2.7%

BIOFRONTERA AG/ADR (NASDAQ:BFRA)’s stock price rose 2.7% during mid-day trading on Friday . The stock traded as high as $11.35 and last traded at $11.35, approximately 100 shares traded hands during mid-day trading. A decline of 84% from the average daily volume of 623 shares. The stock had previously closed at $11.05.

Separately, Lake Street Capital downgraded BIOFRONTERA AG/ADR from a “buy” rating to a “hold” rating and reduced their price objective for the company from $17.00 to $11.00 in a research report on Friday, October 11th.

The company has a debt-to-equity ratio of 0.90, a current ratio of 2.48 and a quick ratio of 2.23. The company has a 50-day moving average price of $12.38 and a 200-day moving average price of $14.71. The firm has a market capitalization of $246.59 million, a PE ratio of 368.33 and a beta of 0.81.

BIOFRONTERA AG/ADR (NASDAQ:BFRA) last issued its quarterly earnings data on Tuesday, August 27th. The company reported $0.58 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.24) by $0.82. BIOFRONTERA AG/ADR had a return on equity of 6.82% and a net margin of 4.48%. The business had revenue of $7.98 million for the quarter.

About BIOFRONTERA AG/ADR (NASDAQ:BFRA)

Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that result in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of actinic keratosis.

Recommended Story: How Investors Can Profit from Options Trading

Receive News & Ratings for BIOFRONTERA AG/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOFRONTERA AG/ADR and related companies with MarketBeat.com's FREE daily email newsletter.